Giovanna Cutrona

List of Publications by Year
in descending order

170 papers	3,965 citations	126858 33 h-index	149623 56 g-index
173 all docs	173 docs citations	173 times ranked	5139 citing authors

#	Article	IF	Citations
1	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. Journal of Clinical Investigation, 2005, 115, 755-764.	3.9	515
2	Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nature Biotechnology, 2000, 18, 300-303.	9.4	229
3	CD38 and chronic lymphocytic leukemia: a decade later. Blood, 2011, 118, 3470-3478.	0.6	181
4	Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood, 2006, 107, 3708-3715.	0.6	107
5	The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood, 2008, 111, 517-524.	0.6	104
6	Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine, 2001, 7, 807-813.	15.2	88
7	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	0.6	86
8	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	0.7	73
9	Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo. Blood, 1999, 94, 3067-3076.	0.6	66
10	B lymphocytes in humans express ZAP-70 when activatedin vivo. European Journal of Immunology, 2006, 36, 558-569.	1.6	60
11	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	3.2	60
12	Molecular and transcriptional characterization of 17p loss in B‑cell chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2008, 47, 781-793.	1.5	59
13	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics, 2011, 6, 188-194.	1.3	58
14	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. American Journal of Hematology, 2016, 91, 1090-1095.	2.0	58
15	Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.. Journal of Experimental Medicine, 1995, 181, 699-711.	4.2	55
16	Nonjudicious Dispensing of Antibiotics by Drug Stores in Pratumthani, Thailand. Infection Control and Hospital Epidemiology, 2008, 29, 572-575.	1.0	54
17	Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion. Clinical Cancer Research, 2010, 16, 5641-5653.	3.2	52
18	High‑throughput sequencing for the identification of *NOTCH1* mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. British Journal of Haematology, 2014, 165, 629-639.	1.2	52

#	Article	IF	Citations
19	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	3.2	52
20	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood, 2016, 128, 2093-2095.	0.6	52
21	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 146, 44-53.	1.2	50
22	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. Frontiers in Oncology, 2020, 10, 593383.	1.3	50
23	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer Journal, 2016, 6, e468-e468.	2.8	47
24	CD26 expression in mature Bâ€cell neoplasia: its possible role as a new prognostic marker in Bâ€CLL. Hematological Oncology, 2009, 27, 140-147.	0.8	46
25	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361.	0.6	45
26	Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica, 2014, 99, 1078-1087.	1.7	43
27	Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica, 2008, 93, 413-422.	1.7	42
28	Constitutive expression of IL-12RÎ²2 on human multiple myeloma cells delineates a novel therapeutic target. Blood, 2008, 112, 750-759.	0.6	38
29	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 612-621.	1.5	38
30	Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. Cancer Gene Therapy, 2007, 14, 220-226.	2.2	37
31	Predictive value of Â2-microglobulin (Â2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica, 2009, 94, 887-888.	1.7	37
32	CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. British Journal of Cancer, 2002, 86, 1776-1785.	2.9	36
33	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. PLoS ONE, 2011, 6, e24313.	1.1	36
34	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Leukemia, 2017, 31, 1894-1904.	3.3	33
35	Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer. Cancer Research, 2003, 63, 6144-8.	0.4	32
36	Therapeutically Promising PNA Complementary to a Regulatory Sequence for c-myc:Pharmacokinetics in an Animal Model of Human Burkitt's Lymphoma. Oligonucleotides, 2005, 15, 85-93.	2.7	29

#	Article	IF	Citations
37	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia, 2016, 30, 1440-1443.	3.3	28
38	Late Epstein-Barr virus infection of a hepatosplenic gamma delta T-cell lymphoma arising in a kidney transplant recipient. Haematologica, 2000, 85, 256-62.	1.7	28
39	Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood, 1991, 78, 797-804.	0.6	27
40	Chromosome 2p gain in monoclonal B€cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	2.0	27
41	Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood, 1999, 94, 3067-76.	0.6	27
42	Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leukemia Research, 2007, 31, 1575-1578.	0.4	25
43	Multiplex ligation€dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study. Genes Chromosomes and Cancer, 2011, 50, 726-734.	1.5	24
44	A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells. Haematologica, 2018, 103, e531-e536.	1.7	24
45	The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein. European Journal of Immunology, 1997, 27, 234-238.	1.6	23
46	Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood, 2001, 97, 2528-2529.	0.6	23
47	Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. European Journal of Haematology, 2010, 85, 314-320.	1.1	23
48	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3150-3158.	0.6	23
49	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. Cells, 2021, 10, 98.	1.8	23
50	The Peptide Nucleic Acid Targeted to a Regulatory Sequence of the Translocated c-myc Oncogene in Burkitt's Lymphoma Lacks Immunogenicity: Follow-Up Characterization of PNAEμ-NLS. Oligonucleotides, 2007, 17, 146-150.	2.7	22
51	Heterogeneous expression and function of IL-21R and susceptibility to IL-21ˆ'mediated apoptosis in follicular lymphoma cells. Experimental Hematology, 2010, 38, 373-383.	0.2	22
52	Retinoic acid induces persistent, RAR?-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines. , 2000, 86, 375-384.		21
53	Igs Expressed by Chronic Lymphocytic Leukemia B Cells Show Limited Binding-Site Structure Variability. Journal of Immunology, 2013, 190, 5771-5778.	0.4	21
54	Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. Blood, 1996, 88, 599-608.	0.6	20

#	Article	IF	Citations
55	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica, 2015, 100, 1460-1468.	1.7	19
56	A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunologic Research, 2015, 63, 90-100.	1.3	18
57	Toll-like receptor 9 stimulation can induce Iî°BÎ¶ expression and IgM secretion in chronic lymphocytic leukemia cells. Haematologica, 2017, 102, 1901-1912.	1.7	18
58	Comparison between the CLLâ€IPI and the <scp>B</scp>arcelonaâ€<scp>B</scp>rno prognostic model: Analysis of 1299 newly diagnosed cases. American Journal of Hematology, 2018, 93, E35-E37.	2.0	18
59	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. British Journal of Haematology, 2020, 189, 853-859.	1.2	18
60	Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood, 2002, 99, 2277-2278.	0.6	17
61	CD5⁺ B cells with the features of subepithelial B cells found in human tonsils. European Journal of Immunology, 2007, 37, 2138-2147.	1.6	17
62	Prognostic relevance of <i>in vitro</i> response to cell stimulation via surface IgD in binet stage a CLL. British Journal of Haematology, 2010, 149, 160-163.	1.2	17
63	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. Molecular Medicine, 2020, 26, 25.	1.9	17
64	Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leukemia Research, 2009, 33, 162-165.	0.4	16
65	Expression of Immunoglobulin Receptors with Distinctive Features Indicating Antigen Selection by Marginal Zone B Cells from Human Spleen. Molecular Medicine, 2013, 19, 294-302.	1.9	16
66	Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. PLoS ONE, 2015, 10, e0134706.	1.1	16
67	The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar. Haematologica, 1997, 82, 542-9.	1.7	16
68	Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica, 2003, 88, 864-73.	1.7	16
69	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer, 2013, 119, 1177-1185.	2.0	15
70	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American Journal of Hematology, 2018, 93, E216-E219.	2.0	15
71	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica, 2020, 105, 1613-1620.	1.7	15
72	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. PLoS ONE, 2015, 10, e0118801.	1.1	15

#	Article	IF	Citations
73	A Retinoic Acid Resistant HL-60 Cell Clone Sensitive to N-(4-hydroxyphenyl) Retinamide-Mediated Clonal Growth Inhibition. Leukemia and Lymphoma, 1995, 17, 155-161.	0.6	14
74	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2014, 89, 743-750.	2.0	14
75	Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. Scientific Reports, 2017, 7, 14159.	1.6	14
76	Cytogenetic Rearrangement of C-MYC Oncogene Occurs Prior to Infection with Epstein-Barr Virus in the Monoclonal Malignant B Cells From an AIDS Patient. Leukemia and Lymphoma, 1993, 9, 157-164.	0.6	13
77	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Science Translational Medicine, 2018, 10, .	5.8	13
78	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. Scientific Reports, 2020, 10, 18427.	1.6	13
79	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. International Journal of Hematology, 2008, 88, 374-380.	0.7	12
80	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Leukemia Research, 2015, 39, 840-845.	0.4	12
81	Apoptosis Induced by Crosslinking of CD4 on Activated Human B Cells. Cellular Immunology, 1999, 193, 80-89.	1.4	11
82	Mutation Pattern of Paired Immunoglobulin Heavy and Light Variable Domains in Chronic Lymphocytic Leukemia B Cells. Molecular Medicine, 2011, 17, 1188-1195.	1.9	11
83	Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients. Scientific Reports, 2020, 10, 16519.	1.6	11
84	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. Non-coding RNA, 2020, 6, 11.	1.3	11
85	PNAEÎ¼ can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease. Cancer Gene Therapy, 2009, 16, 786-793.	2.2	10
86	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2013, 88, 539-544.	2.0	10
87	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 264-273.	1.5	10
88	Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing. Blood Cancer Journal, 2019, 9, 21.	2.8	10
89	Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth. International Journal of Molecular Sciences, 2019, 20, 292.	1.8	10
90	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opinion on Investigational Drugs, 2020, 29, 869-880.	1.9	10

#	Article	IF	Citations
91	Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	2.0	10
92	Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia. Molecular Medicine, 2011, 17, 834-839.	1.9	9
93	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. Leukemia Research, 2013, 37, 943-947.	0.4	9
94	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. British Journal of Haematology, 2015, 168, 455-459.	1.2	9
95	Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Drug Design, Development and Therapy, 2021, Volume 15, 2969-2978.	2.0	9
96	Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. Blood, 2008, 112, 4158-4158.	0.6	9
97	Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines. Haematologica, 2021, 106, 2598-2612.	1.7	9
98	A Retinoic Acid Resistant HL-60 Cell Clone Sensitive to N-(4-hydroxyphenyl) Retinamide-Mediated Clonal Growth Inhibition. Leukemia and Lymphoma, 1995, 17, 175-180.	0.6	8
99	Lymphoblastoid cells transfected with c-myc: Downregulation of EBV-lytic antigens and impaired response of autologousCD4+ T cellsin vitro. , 1996, 68, 810-816.		8
100	Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia. European Journal of Haematology, 2009, 83, 208-214.	1.1	8
101	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	3.3	8
102	Predictive value of the <scp>CLL</scp>‐<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemo‐immunotherapy as first‐line treatment. European Journal of Haematology, 2018, 101, 703-706.	1.1	8
103	<scp><i>TP53</i></scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	2.0	8
104	Production of Inflammatory Cytokines by Epstein-Barr Virus (EBV)-Infected Lymphoblastoid Cell Lines Spontaneously Originated from the Peripheral Blood of Patients with Human Immunodeficiency Virus (HIV)Infection. Clinical Immunology and Immunopathology, 1995, 77, 162-171.	2.1	7
105	Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma. International Journal of Cancer, 2000, 88, 744-750.	2.3	7
106	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O‐<scp>CLL</scp>1‐<scp>GISL</scp> study. European Journal of Haematology, 2016, 96, 36-45.	1.1	7
107	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib‐rituximab. Blood Cancer Journal, 2020, 10, 92.	2.8	7
108	External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience.. Blood, 2009, 114, 2375-2375.	0.6	7

#	Article	IF	Citations
109	Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease,. Blood, 2011, 118, 3890-3890.	0.6	7
110	Studies on the oncogenic potential of epstein-barr-virus (EBV)-infected B cells in aids-related disorders. International Journal of Cancer, 1989, 44, 78-82.	2.3	6
111	Heterogeneousp53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonalc-myc andVDJ rearrangements. , 1997, 73, 816-821.		6
112	B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. Journal of Clinical Pathology, 2007, 60, 627-632.	1.0	6
113	Epigenetic mechanisms regulate Î”NP73 promoter function in human tonsil B cells. Molecular Immunology, 2011, 48, 408-414.	1.0	6
114	Validation of the Alternative International Prognostic Scoreâ€‹ (AIPSâ€‹): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the Oâ€‹CLL1â€‹GISL protocol. European Journal of Haematology, 2021, 106, 831-835.	1.1	6
115	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 684621.	1.3	6
116	Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia. Current Molecular Medicine, 2017, 17, 24-33.	0.6	6
117	Lack of mutagenicity and clastogenicity of PNAEÎ¼-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 628, 129-137.	0.9	5
118	Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression. Blood Cancer Journal, 2017, 7, e513-e513.	2.8	5
119	Frequency and clinical relevance of coding and noncoding <i>NOTCH1</i> mutations in early stage Binet A chronic lymphocytic leukemia patients. Hematological Oncology, 2020, 38, 406-408.	0.8	5
120	Comparison of ibrutinib and idelalisib plus rituximab in realâ€‹life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	1.1	5
121	LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. Hematological Oncology, 2022, 40, 41-48.	0.8	5
122	Transforming growth factor beta-1 (TGF-Î²1) released by an Epstein-Barr virus (EBV) positive spontaneous lymphoblastoid cell line from a patient with Kostmann's congenital neutropenia inhibits the growth of normal committed haemopoietic progenitors in vitro. British Journal of Haematology, 1993, 85, 684-691.	1.2	4
123	H and L Ferritin Gene Expression in U937 Cells Induced to Macrophage Differentiation. Leukemia and Lymphoma, 1993, 12, 109-115.	0.6	4
124	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. Leukemia and Lymphoma, 2008, 49, 62-67.	0.6	4
125	Prognostic factors in CLL. Leukemia Supplements, 2012, 1, S29-S30.	0.1	4
126	A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). Clinical Immunology, 2016, 172, 52-60.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements. Frontiers in Oncology, 0, 12, .	1.3	4
128	C-Myc Proto-oncogene Expression by Germinal Center B Cells Isolated from Human Tonsils. Annals of the New York Academy of Sciences, 1997, 815, 436-438.	1.8	3
129	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. Leukemia Research, 2010, 34, e217-e218.	0.4	3
130	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opinion on Pharmacotherapy, 2020, 21, 29-38.	0.9	3
131	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. Cell Reports, 2021, 34, 108845.	2.9	3
132	Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	2.0	3
133	MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 4172-4172.	0.6	3
134	MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. Blood Advances, 2022, 6, 5593-5612.	2.5	3
135	Identification of HSP-60 as the specific antigen of IgM produced by BRG-lymphoma cells. Electrophoresis, 1999, 20, 1092-1097.	1.3	2
136	More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia. Leukemia Research, 2010, 34, e326-e328.	0.4	2
137	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. Blood, 2010, 116, 1360-1360.	0.6	2
138	Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. International Journal of Oncology, 1997, 11, 1203-8.	1.4	1
139	International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S278.	0.2	1
140	INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematological Oncology, 2019, 37, 81-82.	0.8	1
141	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. Blood, 2018, 132, 1834-1834.	0.6	1
142	Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. Blood, 2008, 112, 4187-4187.	0.6	1
143	The Total Amount of Kappa Plus Lambda Serum Immunoglobulin Free Light Chains (sFLC κ+λ) Is a Powerful Independent Predictor of Time to First Treatment In Chronic Lymphocytic Leukemia (CLL) and Allows Definition of a Novel Prognostic Scoring System: A Study of 449 Therapy-naïve Patients. Blood, 2010, 116, 2437-2437.	0.6	1
144	Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2328-2328.	0.6	1

#	Article	IF	Citations
145	Stereotyped Subset #4 In Chronic Lymphocytic Leukemia Is Associated With Distinct Gene and Microrna Transcriptional Profile. Blood, 2013, 122, 1616-1616.	0.6	1
146	Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo. Blood, 1999, 94, 3067-3076.	0.6	1
147	Microenvironment Regulation of IL23R/IL-23 Axis Drives Chronic Lymphocytic Leukemia (CLL) Progression. Blood, 2015, 126, 616-616.	0.6	1
148	Cellular and Molecular Characterization of Two Cases of Castleman's Disease, Plasma Cell Variant. Leukemia and Lymphoma, 1991, 5, 391-396.	0.6	0
149	1.2 Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of CLL. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S141-S142.	0.2	0
150	The Response to Surface IgM and IgD Cross-Linking Defines Different Groups of B-CLL.. Blood, 2005, 106, 177-177.	0.6	0
151	Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2786-2786.	0.6	0
152	Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3093-3093.	0.6	0
153	The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features.. Blood, 2007, 110, 2077-2077.	0.6	0
154	CD26 Expression in Mature B-Cell Neoplasia: Its Possible Role as a New Prognostic Marker in B-CLL.. Blood, 2007, 110, 4670-4670.	0.6	0
155	Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers.. Blood, 2008, 112, 1061-1061.	0.6	0
156	Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1062-1062.	0.6	0
157	Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative.. Blood, 2009, 114, 1259-1259.	0.6	0
158	Incidence of Cytogenetic Abnormalities in Newly Diagnosed Binet Stage A B-CLL and Relationship with Prognostic Biomarkers: Preliminary Results On 305 Patients Included in the Prospective O-CLL1 GISL Study.. Blood, 2009, 114, 2341-2341.	0.6	0
159	Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study.. Blood, 2010, 116, 4613-4613.	0.6	0
160	Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group. Blood, 2010, 116, 2423-2423.	0.6	0
161	Abstract 1229: Prognostic significance of telomere length in B-chronic lymphocytic leukemia patients in early stage disease. , 2011, , .		0
162	Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY. Blood, 2011, 118, 2837-2837.	0.6	0

#	Article	IF	Citations
163	The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis. Blood, 2012, 120, 3889-3889.	0.6	0
164	BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis. Blood, 2012, 120, 3934-3934.	0.6	0
165	High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications. Blood, 2013, 122, 1622-1622.	0.6	0
166	Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood, 1991, 78, 797-804.	0.6	0
167	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3314-3314.	0.6	0
168	Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis. Blood, 2015, 126, 1729-1729.	0.6	0
169	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2930-2930.	0.6	0
170	PF365âPROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH â€œBORDERLINEâ€•PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. HemaSphere, 2019, 3, 134-135.	1.2	0